Skip to main content

Psychedelic drug studies face a potent source of bias: the ‘trip’

Charles Raison, a psychiatrist at the University of Wisconsin–Madison, has been experimenting with having people sleep through their trips, as a way to understand how much a conscious psychedelic experience matters. Two volunteers received psilocybin while in a deep sleep with a sedative, and 1 week later both “swore they got placebo,” Raison says. He is now developing a larger study in which people with self-reported reduced emotional well-being will be randomized to get psilocybin or placebo while either awake or asleep, to tease out how the trip influences longer term effects on emotional state.